24 Jul, 2023

LundCast 29 | Ansiedade e Irritabilidade no TDM | Part. Dr. Marcio Bernik

Confira abaixo a parte dois do episódio e veja o separata contendo o caso clínico.

 

Lundcast Ep.29 - Ansiedade e Irritabilidade no TDM (PARTE 2)

 

 

CLIQUE AQUI para ouvir a PARTE 01 do episódio no Spotify

 

Participantes:

  • Dr. Marcio Bernik - Psiquiatra (CRM-SP: 51358 / RQE: 115548)
  • Nicholas Ferreira - Coordenador de Iniciativas Digitais Lundbeck Brasil

 

 

O uso do brexpiprazol nos tratamentos de sintomas ansiosos e da irritabilidade na depressão
Dr. Marcio Bernik - O uso do brexpiprazol nos tratamentos de sintomas ansiosos e de irritabilidade na depressão_2.PDF (671.74 KB)

Referências

1. American Psychiatric Association (APA). Manual Diagnóstico e Estatítico de Transtornos Mentais. DSM-IV. 4.ª ed. Porto Alegre: Artmed; 2002.

2. American Psychiatric Association (APA). Manual diagnóstico e estatístico de transtornos mentais: DSM-IV-TRTM. 4.ª ed. rev. Porto Alegre: Artmed; 2002.

3. American Psychiatric Association (APA). Manual diagnóstico e estatístico de transtornos mentais: DSM-5. 5.ª ed. Porto Alegre: Artmed; 2014.

4. American Psychiatric Association (APA). Manual diagnóstico e estatístico de transtornos mentais: DSM-5-TR. 5.ª ed. rev. Porto Alegre: Artmed; 2023.

5. Schatzber AF, Debattista C. Schatzberg’s Manual of Clinical Psychopharmacology. 9th ed. Washington, DC: American Psychiatric Pub; 2019.

6. Davis LL, Ota A, Perry P, Tsuneyoshi K, Weiller E, Baker RA. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain Behav. 2016; 6(10):e00520.

7. Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry. 2008 Dec;69(12):1928-36.

8. Bandelow B, Bauer M, Vieta E, El-Khalili N, Gustafsson U, Earley WR, et al. Extended-release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. World J Biol Psychiatry. 2014;15(2):155-66.

9. Perlis RH, Fraguas R, Fava M, Trivedi MH, Luther JF, Wisniewski SR, et al. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry. 2005; 66(2):159-66.

10. Perlis RH, Fava M, Trivedi MH, Alpert J, Luther JF, Wisniewski SR, et al. Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatr Scand. 2009;119(4):282-9.

11. Fava M, Hwang I, Rush AJ, Sampson N, Walters EE, Kessler RC. The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(8):856-67.

12. Savage J, Verhulst B. Copeland W, Althoff RR, Lichtenstein P, Roberson-Nay R. A genetically informed study of the longitudinal relation between irritability and anxious/depressed symptoms. J Am Acad Child Adolesc Psychiatry. 2015;54(5):377-84.

13. Stringaris A, Cohen P, Pine DS, Leibenluft E. Adult outcomes of youth irritability: a 20-year prospective community-based study. Am J Psychiatry. 2009 Sep;166(9):1048-54.

14. Boudreaux ED, Larkin C, Kini N, Capoccia L, Allen MH, Goldstein Grumet J, et al. Predictive utility of an emergency department decision support tool in patients with active suicidal ideation. Psychol Serv. 2018;15(3):270-8.

15. Stahl SM, Grady MM, Muntner N. Stahl’s essential psychopharmacology : neuroscientific basis and practical applications. 5th ed. Cambridge: Cambridge University Press; 2021.

16. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905-17.

17. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry. 1991;52 Suppl:28-34.

18. Ramana R, Paykel ES, Cooper Z, Hayhurst H, Saxty M, Surtees PG. Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med. 1995;25(6):1161-70.

19. Flint AJ, Rifat SL. Two-year outcome of elderly patients with anxious depression. Psychiatry Res. 1997;66(1):23-31.

20. Oquendo MA, Currier D, Mann JJ. Prospective studies of suicidal behavior in major depressive and bipolar disorders: what is the evidence for predictive risk factors? Acta Psychiatr Scand. 2006;114(3):151-8.

21. Ballard ED, Vande Voort JL, Luckenbaugh DA, Machado-Vieira R, Tohen M, Zarate CA. Acute risk factors for suicide attempts and death: prospective findings from the STEP-BD study. Bipolar Disord. 2016;18(4):363-72.

22. Orri M, Perret LC, Turecki G, Geoffroy MC. Association between irritability and suicide-related outcomes across the life-course. Systematic review of both community and clinical studies. J Affect Disord. 2018 Oct 15;239:220-33.

23. Jha MK, Minhajuddin A, South C, Rush AJ, Trivedi MH. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. Am J Psychiatry. 2019;176(5):358-66.

24. Fava M, Ménard F, Davidsen CK, Baker RA. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study. J Clin Psychiatry. 2016 Dec;77(12):1695-701.

25. Stahl SM. Fundamentos de Psicofarmacologia de Stahl: Guia de Prescrição. 6.ª ed. Porto Alegre: Artmed; 2019.

26. Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015 Sep;76(9):1224-31.

27. Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015 Sep;76(9):1232-40.

28. Siwek M, Wojtasik-Bakalarz K, Krupa AJ, Chrobak AA. Brexpiprazole-Pharmacologic Properties and Use in Schizophrenia and Mood Disorders. Brain Sci. 2023;13(3):397.

29. Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605-14.

30. Ichinose M, Miura I, Horikoshi S, Yamamoto S, Kanno-Nozaki K, Watanabe K, et al. Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder. Neuropsychiatr Dis Treat. 2021;17:1047-53.

31. McIntyre RS, Weiller E, Zhang P, Weiss C. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials. J Affect Disord. 2016;201:116-23.